Black Hawk Acquisition Corporation
BKHA evidence brief
What we can confirm
- Market Cap:
- $49.8M
What it means
What to watch
Prepared research question
What matters most for BKHA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BKHA
Black Hawk Acquisition Corporation (BKHA) is a Cayman Islands exempted company formed as a blank-check acquisition vehicle that has entered into a business combination agreement with Vesicor Therapeutics, Inc., a California-based biotech firm, and plans to domesticate as a Delaware corporation and change its name to Vesicor T upon closing.
Key risk: Zero cash position
Market Cap
$49.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of May 31, 2026.
Black Hawk Acquisition Corporation (BKHA) is a Cayman Islands exempted company formed as a blank-check acquisition vehicle that has entered into a business combination agreement with Vesicor Therapeutics, Inc., a California-based biotech firm, and plans to domesticate as a Delaware corporation and change its name to Vesicor T upon closing.
- Black Hawk Acquisition Corporation is a blank-check company formed to enter into a business combination with one or more target businesses [sec_mda · as of 2026-03-06].
- On April 26, 2025, the Company entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. and BH Merger Sub, Inc. to consummate a business combination [sec_mda · as of 2026-03-06].
- As of 2026-05-31, the Company reported cash & equivalents of $0.0M, net income of $0.1M, shareholders' equity of -$5.1M, and total debt of $0.0M [sec].
- On September 22, 2026, BKHA and Vesicor entered into a forward purchase agreement with Meteora for up to 1.35M shares; the Company plans to domesticate as a Delaware corporation and change its name to Vesicor T [news · published 2026-09-24].
- The Company's management team includes Dr. Tolentino, who co-founded Aikium, Inc. and helped invent and pre-clinically develop Avastin with Genentech [sec · filed 2026-03-17].
What works
- The Company has identified a specific target (Vesicor Therapeutics) and executed a Business Combination Agreement, providing a clear path forward [sec_mda · as of 2026-03-06].
- Management includes Dr. Tolentino, a co-founder of Aikium and a key figure in the development of Avastin, indicating deep industry expertise [sec · filed 2026-03-17].
- A forward purchase agreement with Meteora for up to 1.35M shares suggests ongoing capital market support for the business combination [news · published 2026-09-24].
What to weigh
- The Company has negative shareholders' equity of -$5.1M as of 2026-05-31, indicating a structural capital deficit [sec].
- Cash and equivalents are $0.0M as of 2026-05-31, meaning the Company has no cash on hand to fund operations or the business combination [sec].
- The business combination is subject to numerous risks, including termination events, legal proceedings, and financing risks, as described in the Company's filings [sec · filed 2025-04-29].
- The Company is a blank-check entity with no operating history or revenue, making its future entirely dependent on the success of the proposed business combination [sec_mda · as of 2026-03-06].
From the filings
Quoted directly from source documents.
The Company entered into a Business Combination Agreement with Vesicor Therapeutics.
“On April 26, 2025, we entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. and BH Merger Sub, Inc.”
SEC MD&A · March 6, 2026
The Company plans to domesticate as a Delaware corporation and change its name to Vesicor T.
“Company To Domesticate As A Delaware Corporation And Change Name To Vesicor T”
News · September 24, 2026
Dr. Tolentino helped invent and pre-clinically develop Avastin.
“he helped invent and pre-clinically develop Avastin with Genentech”
SEC filings · March 17, 2026
Risks & what to watch (4)›
Key risks
- Zero cash position — Cash & equivalents of $0.0M as of 2026-05-31, meaning no liquidity to fund operations or the business combination [sec].
- Negative shareholders' equity — Shareholders' equity of -$5.1M as of 2026-05-31, indicating a structural capital deficit [sec].
- Business combination risks — The business combination is subject to termination, legal proceedings, and financing risks as described in SEC filings [sec · filed 2025-04-29].
- No operating history — The Company is a blank-check entity with no revenue or operations, making it entirely dependent on the proposed business combination [sec_mda · as of 2026-03-06].
What to watch
- Completion of the business combination with Vesicor Therapeutics, including the domestication as a Delaware corporation and name change to Vesicor T [news · published 2026-09-24].
- Execution of the forward purchase agreement with Meteora for up to 1.35M shares and its impact on the Company's capital position [news · published 2026-09-24].
- Any legal proceedings or regulatory hurdles that may delay or terminate the business combination [sec · filed 2025-04-29].
- The Company's ability to secure additional financing given its zero cash position and negative equity [sec].
Sources: News · SEC filings · SEC MD&A · Generated September 27, 2026 · How we verify sources →
Run Black Hawk Acquisition Corporation through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Black Hawk Acquisition Corporation facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 20, 2026- % of float
- 0.0%
- Days to cover
- 0.2
- Shares short
- 106
- Daily short volume (Oct 9, 2026)
- 78.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BKHA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Black Hawk Acquisition Corporation?
Black Hawk Acquisition Corporation (BKHA) is a Cayman Islands exempted company formed as a blank-check acquisition vehicle that has entered into a business combination agreement with Vesicor Therapeutics, Inc., a California-based biotech firm, and plans to domesticate as a Delaware corporation and change its name to Vesicor T upon closing.
Who is the CEO of Black Hawk Acquisition Corporation?
Mr. Kent Louis Kaufman is the chief executive officer of Black Hawk Acquisition Corporation (BKHA).
Where is Black Hawk Acquisition Corporation headquartered?
Black Hawk Acquisition Corporation (BKHA) is headquartered in Danville, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.